NAMPT and metabolic dysfunction-associated steatotic liver disease: eNAMPT is prominently released from multiple cells including innate immunity effector cells, epithelial cells, and endothelial cells18 as well as adipocytes as the adipokine, visfatin, with eNAMPT plasma levels increased in patients with obesity, metabolic syndrome insulin resistance, and type 2 diabetes mellitus.18,30–32 The current study was designed to investigate eNAMPT involvement in driving NAFLD severity and progression to hepatic fibrosis.